In June 2021 , China officially ushered in the first approved CAR-T cell therapy product , marking the first year of China's entry into cell and gene therapy, and the era of cell gene therapy represented by CAR-T has begun. At present, the number of clinical pipelines of cell and gene therapy is increasing year by year, and will usher in a commercial boom. In the next 5 to 10 years, more cell therapy products will be approved in China. Cell and gene therapy has become one of the most competitive emerging fields in the global biotechnology field.
According to Frost & Sullivan's forecast, the market size of the domestic CAR-T therapy will be RMB 200 million in 2021, and is expected to reach RMB 5.3 billion in 2024, and further increase to RMB 28.9 billion in 2030, with a compound annual growth rate of 45.0% from 2022 to 2030.
In the field of gene therapy, as of September 2021, 856 gene therapy (including RNA therapy) clinical trial plans have been registered on the Clinical Trial website worldwide, of which 576 are in the United States, ranking first, followed by 402 in Europe, and 45 in China. In August 2021, China's first systemically administered rare disease gene therapy was clinically approved, opening a new chapter in China's AAV gene therapy.
In most therapeutic areas, cell and gene therapies have the potential to play a vital role in reshaping the way we think and in the way medicine and disease are treated. However, the road to success for these revolutionary therapies is still paved with technical and commercial hurdles that need to be overcome before cell and gene therapies can reach their full potential. Driven by multiple factors such as favorable policies, scientific and technological progress, and capital support, China's cell and gene therapy industry is developing rapidly, clinical research is in full swing, and the market scale is growing rapidly. The continuous optimization of technology and supply chain is an inevitable development trend.
In order to promote the integration of upstream and downstream industries and the transformation of scientific and technological achievements, the first CGT Asia was successfully held in Shanghai in March 2021. It was full of guests, 600+ industry experts attended the summit site, and 30+ high-quality exhibitors set up a booth to share professional technologies and solutions face to face. At the same time, the first CGT Asia gathered nearly 100 domestic and international leading pharmaceutical companies. Experts actively discussed hot topics and discussed opportunities for industrial innovation. On this basis, the 2nd Asian Cell and Gene Therapy Innovation Summit of CGT Asia 2022 hosted by Taas Labs will be held in Shanghai from July 10th to 11th, 2022.
The annual CGT Asia integrates high-quality resources at home and abroad and the whole industry, grasps the industry trend from a professional perspective, and sets off a "ideological storm". This summit will have 30+ domestic and foreign industry leaders share their experience, insights and application cases, interpret the latest trends and ideas in the industry, and gain insight into industry development and new trends.
Some exciting topics
- Outlook for Cell Therapy Product Launches
- Development of novel tumor immunotherapy
- NK cell-based immunotherapy
- The challenge of TCR-T/TIL/CAR-NK cells in the treatment of solid tumors
- iPSC Personalized Diagnosis and Application
- Pain points and difficulties in the development of RNA nucleic acid drugs
- Clinical practice and difficulties of dual-target CAR-T
- Gene Editing Boosts Cell Therapy Techniques
- AAV virus vector process optimization scheme
- Difficulties and Pain Points in the Development of Rare Disease Gene Therapy Drugs
- GMP production and IND declaration experience sharing for gene therapy and other projects
Previous wonderful review
Some past speakers
Mao Hua, Partner and Managing Director, Frost & Sullivan
Professor on the left, chairman, chief scientist/professor, doctoral supervisor, Jimmy Ruisheng/Tongji University School of Medicine
Dr. Lin Jian, Senior Director of External Innovation, Johnson & Johnson
Dr. Chang Yan, President, Enox-National Shanghai Center for Drug Safety Evaluation and Research
Dr. Jiang Xinpo, Senior Director, Nanjing Legend Biotechnology Co., Ltd.
Dr. Ni Dongyao, Chief Operating Officer/Director of Clinical Operations, Shenzhen Yinuowei Pharmaceutical Co., Ltd.
Dr. Shuyuan Yao, Chief Scientific Officer, Head of R&D and Technology Development, WuXi AppTec Advanced Therapeutics Division
Prof. Yingjie Xu, Researcher/Scientific Founder, Shanghai Jiaotong University School of Medicine/Shanghai Lanque Biomedicine
Dr. Zhang Yu, Deputy General Manager and Chief Scientific Officer, Zhongyuan Xiehe Cell Gene Engineering Co., Ltd.
Dr. Dong Changgui, Deputy General Manager/Technical Director, Shanghai Gemma Pharmaceutical Co., Ltd.
Dr. Wang Min, Technical Director, Biosunji Pharmaceutical Technology (Suzhou) Co., Ltd.
Dr. Erin PIAZZA, Senior Bioinformatician, NanoString Technologies
Part of the previous participating companies
中国科学院上海药物研究所，上海市生物医药行业协会，上海交通大学医学院，华东理工大学医学院，瑞金医院，贵州医科大学，遵义医科大学附属医院，上海细胞治疗集团，药明巨诺，复星凯特，武田制药，安进，默克，默沙东，渤健，南京传奇生物，金斯瑞，信达生物，百济神州 ，天境生物，西比曼，中源协和，恒润达生，药明康德，国药集团，上药集团，三生国健，齐鲁制药，华大吉诺因，蓝鹊生物，亘喜生物，重庆精准生物，中美冠科，吉玛制药，臻知医学，卡替医疗，北恒生物，东曜药业，斯丹赛，元宋生物，君赛生物，恒瑞源正，丹瑞生物，北科生物，霍德生物，可瑞生物，吉倍生物，华道生物，浙江健新原力，养生堂，原启生物，普米斯生物技术等